TC
NKTR icon

Talkot Capital’s Nektar Therapeutics NKTR Stock Holding History

Talkot Capital’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-1,667
Closed -$275K – 24
2015
Q1 		$275K Buy
+1,667
New +$343K 0.19% 26

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Talkot Capital's NKTR Position: Q2 2015 in Review

Talkot Capital sold out of Nektar Therapeutics (NKTR) in Q2 2015, closing a stake of 1,667 shares — an estimated $275K sold.

Talkot Capital first reported a position in NKTR in Q1 2015 and held it in 1 quarter. The position peaked at $275K in Q1 2015. 181 funds tracked by Wall St. Rank hold NKTR as of Q2 2015.

  • Talkot Capital reported no remaining Nektar Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Talkot Capital sold 1,667 Nektar Therapeutics shares in Q2 2015, an estimated $275K.
  • Talkot Capital first reported a position in Nektar Therapeutics in Q1 2015 and held it in 1 quarter.
  • Talkot Capital's Nektar Therapeutics position peaked at $275K in Q1 2015.
  • 181 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2015.

Based on Talkot Capital's 13F filing for Q2 2015, filed 13 Aug 2015.